Global Life Sciences
Overview
Featured News & Insights
0018
Contacts
Services
Advising on the full scope of regulatory, compliance and enforcement, litigation and transactional matters, we can offer you a holistic legal approach that will smooth your path as you navigate industry changes, technological advances, market demands and policy hurdles.
Regions
From high-profile transactions to regulatory issues and complex litigation, we collaborate across borders and disciplines to help our clients in more than 70 countries face challenges and embrace opportunities.

All Professionals
sort


Capabilities
- Antitrust and Competition
- Capital Markets
- Commercial Litigation and Disputes
- Emerging Companies and Venture Capital
- Environmental, Health, and Safety
- Food, Drug and Medical Device
- Global Arbitration, Trade and Advocacy
- Government Strategies
- Healthcare
- IP Litigation
- M&A
- Privacy and Cybersecurity
- Private Equity
- Product Liability and Mass Torts
- Technology
- Technology and Life Sciences Transactions
Related Resources
Related Blogs
News & Insights
Bay Area Life Sciences RoundtableWednesday, July 22, 2026Sidley & Life Science Cares Reception at BIO 2026Monday, June 22, 2026Boston Life Sciences RoundtableTuesday, June 9, 2026Sidley Sponsors the 2026 EU Pharma Law ForumTuesday, May 19, 2026 – Thursday, May 21, 2026
Conferences
Receptions
Conferences
Events
U.S. FDA Issues First Drug Supply Chain Security Act Warning Letter Targeting a Dispenser, Signaling Expanded Enforcement FocusApril 15, 2026#Market Access: Another Favorable Medical Products Advisory Opinion from HHS-OIG Signals New FlexibilitiesMarch 19, 2026New U.S. FDA Letter Contradicts Decades-Old Precedent on Prescription Drug PromotionMarch 10, 2026New U.S. DOJ Antitrust Leadership Signals More Criminal Prosecutions and Longer Prison SentencesMarch 6, 2026
Food, Drug, and Medical Device Update
Global Life Sciences Update
Global Life Sciences Update
Antitrust and White Collar Defense and Investigations Update
Congress Passes Significant Federal Pharmacy Benefit Manager Reform Impacting Pharmaceutical Market AccessApril 9, 2026FDA's Crackdown On Drug Ads Conflicts With PrecedentApril 2, 2026Drug Pricing and Medicaid Rebate Reporting: Enforcement Risk RemainsFebruary 17, 2026Legal Issues Arising From the Use of Artificial Intelligence in Drug DevelopmentFebruary 11, 2026
Westlaw Today
Law360
Reuters
Drug Discovery World
Bay Area Life Sciences RoundtableWednesday, July 22, 2026Sidley & Life Science Cares Reception at BIO 2026Monday, June 22, 2026Boston Life Sciences RoundtableTuesday, June 9, 2026Sidley Sponsors the 2026 EU Pharma Law ForumTuesday, May 19, 2026 – Thursday, May 21, 2026
Conferences
Receptions
Conferences
Events
Sidley Represents Neomorph in Its US$100 Million Series B FinancingApril 15, 2026Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from TakedaApril 3, 2026Sixteen Sidley Partners Selected to Serve on Law360’s 2026 Editorial BoardsMarch 30, 2026Sidley Represents Salt & Stone in Majority Stake Acquisition by AdventMarch 24, 2026
Announcements
Announcements
Announcements
Announcements
Sidley Wins Three Awards at the Managing IP Americas Awards 2026April 10, 2026Nineteen Sidley Lawyers Named Finalists for the Women in Business Law Americas Awards 2026April 2, 2026Sidley Recognized in Legal 500 EMEA 2026March 25, 2026Sidley Ranked in Chambers Europe 2026March 19, 2026
Accolades
Accolades
Accolades
Accolades
Navigating the European Health Data Space Regulation: An (Uneasy) Marriage Between EHDS and GDPR (April 2026, Part 2)April 14, 2026TX AG’s Office Continues Aggressive Enforcement Against Healthcare Entities Operating in TexasFebruary 25, 2026DAAG Brenna Jenny Warns Heightened FCA Enforcement Is “The New Normal,” Addresses Enforcement Priorities and PoliciesFebruary 20, 2026Delaware Supreme Court Makes Earnouts Less Risky For Buyers Earnout Decision Partially Reversed Because Buyer Did Not Have to Pursue an Alternative Regulatory PathwayJanuary 27, 2026
GoodLifeSci
Original Source
Original Source
GoodLifeSci
Renewed Market Optimism @ JPM 2026January 12, 2026What's Ahead for Life Sciences Dealmaking @ JPM 2026January 12, 2026Top 10 FDA Areas We Are Watching @ JPM 2026January 12, 2026Regulatory Considerations for the Next Wave of Development-Stage Transactions @ JPM 2026January 12, 2026
Videos
Videos
Videos
Videos








































